Hutch News

Hutch News

Stories tagged 'Transplant and Immunotherapy'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Aug. 17, 2017

Dr. Filippo Milano and colleagues in the Cord Blood Program at Fred Hutch have received funding from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation to support a clinical trial to improve the use of umbilical cord blood as a treatment for leukemia ... and more good news at Fred Hutch.

View story >


New integrated research center launches

Dr. Denise Galloway heads new collaborative center to study prevention and treatment of cancers linked to infectious agents

Aug. 10, 2017 | By Sabrina Richards / Fred Hutch News Service

Dr. Denise Galloway heads new collaborative center to research prevention and treatment of infection-related cancers

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Aug. 3, 2017

Fred Hutch's Dr. Slobodan Beronja and colleagues at Yale University have published new findings in Nature that show healthy skin cells can fight off the cancerous tendencies of nearby cells that harbor cancer-causing mutations.

View story >


6 things to know about glioblastoma

Following Sen. John McCain’s diagnosis, Fred Hutch experts offer ‘the long view’ on brain cancer research

July 21, 2017 | By Mary Engel / Fred Hutch News Service

Our experts at Fred Hutchinson Cancer Research Center offer the long view on glioblastoma diagnosis, treatment and research in light of Sen. John McCain's recent diagnosis.

View story >


How cancer fools healthy neighboring cells

‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients

July 18, 2017 | By Rachel Tompa / Fred Hutch News Service

Like tiny con men, cancer cells have many tricks to fool healthy cells into helping them. Research into the "tumor microenvironment" is uncovering new avenues for treatment.

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.